secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2026-06-09T22:11:53+00:00
Accession:  0001193125-26-264392
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Director Brian Thomas resigns from Metagenomi board; shareholders re-elect Eckhardt, Bjerkholt and ratify PwC as auditor
--------------------------------------------------------------------------------

- Brian C. Thomas, Ph.D. resigned from the board effective June 9, 2026, with no disagreement with the company.
- Juergen Eckhardt and Eric Bjerkholt elected as Class II directors to serve until 2029 annual meeting.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 18,483,295 votes for, 51,847 against.
- Quorum of 19,116,207 shares present out of 37,647,057 outstanding at the June 9, 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/0001193125-26-264392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/mgx-20260609.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-264392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer